Corynebacterium jeikeium: Difference between revisions
From IDWiki
Corynebacterium jeikeium
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
* Species of [[Corynebacterium|''Corynebacterium'']] that causes opportunistic infections, most closely associated with hematologic stem cell transplant patients |
* Species of [[Corynebacterium|''Corynebacterium'']] that causes opportunistic infections, most closely associated with hematologic stem cell transplant patients |
||
* Clinical presentations include bacteremia, prosthetic valve endocarditis, meningitis, and peritonitis |
* Clinical presentations include bacteremia, prosthetic valve endocarditis, meningitis, and peritonitis |
||
* Essentially universally susceptible to [[vancomycin]] and [[linezolid]] |
|||
* High rates of resistance to beta lactams; may be fluoroquinolone or tetracycline susceptible<ref name=":0">Neemuchwala A, Soares D, Ravirajan V, Marchand-Austin A, Kus JV, Patel SN. ''In Vitro'' Antibiotic Susceptibility Pattern of Non-diphtheriae Corynebacterium Isolates in Ontario, Canada, from 2011 to 2016. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e01776-17. doi: [https://doi.org/10.1128/aac.01776-17 10.1128/AAC.01776-17]. PMID: [https://pubmed.ncbi.nlm.nih.gov/29339389/ 29339389]; PMCID: [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5914010/ PMC5914010].</ref> |
|||
{| class="wikitable sortable" |
|||
|+From <ref name=":0" /> |
|||
!Antibiotic |
|||
!Isolates |
|||
!% Susceptible |
|||
|- |
|||
|[[Penicillin]] |
|||
|76 |
|||
|0 |
|||
|- |
|||
|[[Ampicillin]] |
|||
|76 |
|||
|ND |
|||
|- |
|||
|[[Oxacillin]] |
|||
|76 |
|||
|ND |
|||
|- |
|||
|[[Erythromycin]] |
|||
|76 |
|||
|11.8 |
|||
|- |
|||
|[[Clindamycin]] |
|||
|76 |
|||
|2.6 |
|||
|- |
|||
|[[Ciprofloxacin]] |
|||
|75 |
|||
|35.5 |
|||
|- |
|||
|[[Levofloxacin]] |
|||
|75 |
|||
|ND |
|||
|- |
|||
|[[Moxifloxacin]] |
|||
|76 |
|||
|35.5 |
|||
|- |
|||
|'''[[Tetracycline]]''' |
|||
|'''76''' |
|||
|'''92.1''' |
|||
|- |
|||
|'''[[Vancomycin]]''' |
|||
|'''76''' |
|||
|'''100''' |
|||
|- |
|||
|[[Trimethoprim-sulfamethoxazole]] |
|||
|76 |
|||
|18.4 |
|||
|- |
|||
|[[Tigecycline]] |
|||
|76 |
|||
|ND |
|||
|- |
|||
|'''[[Rifampin]]''' |
|||
|'''76''' |
|||
|'''97.4''' |
|||
|- |
|||
|'''[[Quinupristin-dalfopristin]]''' |
|||
|'''76''' |
|||
|'''89.5''' |
|||
|- |
|||
|'''[[Linezolid]]''' |
|||
|'''76''' |
|||
|'''100''' |
|||
|- |
|||
|'''[[Gentamicin]]''' |
|||
|'''76''' |
|||
|'''81.6''' |
|||
|- |
|||
|'''[[Daptomycin]]''' |
|||
|'''75''' |
|||
|'''89.5''' |
|||
|- |
|||
|[[Chloramphenicol]] |
|||
|75 |
|||
|ND |
|||
|- |
|||
|[[Nitrofurantoin]] |
|||
|76 |
|||
|ND |
|||
|} |
|||
{| class="wikitable" |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|Penicillin |
|||
|76 |
|||
|0.5 to >8 |
|||
|>8 |
|||
|>8 |
|||
|0 |
|||
|- |
|||
| Ampicillin |
|||
|76 |
|||
|≤0.12 to >8 |
|||
|>8 |
|||
|>8 |
|||
|ND |
|||
|- |
|||
| Oxacillin |
|||
|76 |
|||
|0.5 to >4 |
|||
|>4 |
|||
|>4 |
|||
|ND |
|||
|- |
|||
| Erythromycin |
|||
|76 |
|||
|≤0.25 to >4 |
|||
|>4 |
|||
|>4 |
|||
|11.8 |
|||
|- |
|||
| Clindamycin |
|||
|76 |
|||
|≤0.5 to >2 |
|||
|>2 |
|||
|>2 |
|||
|2.6 |
|||
|- |
|||
| Ciprofloxacin |
|||
|75 |
|||
|≤1 to >2 |
|||
|>2 |
|||
|>2 |
|||
|35.5 |
|||
|- |
|||
| Levofloxacin |
|||
|75 |
|||
|≤0.25 to >4 |
|||
|>4 |
|||
|>4 |
|||
|ND |
|||
|- |
|||
| Moxifloxacin<sup>''b''</sup> |
|||
|76 |
|||
|≤0.25 to >4 |
|||
|4 |
|||
|>4 |
|||
|35.5 |
|||
|- |
|||
| Tetracycline |
|||
|76 |
|||
|≤2 to >16 |
|||
|≤2 |
|||
|≤2 |
|||
|92.1 |
|||
|- |
|||
| Vancomycin |
|||
|76 |
|||
|≤0.25 to 2 |
|||
|0.50 |
|||
|1 |
|||
|100 |
|||
|- |
|||
| Trimethoprim-sulfamethoxazole |
|||
|76 |
|||
|≤0.5 to >4 |
|||
|>4 |
|||
|>4 |
|||
|18.4 |
|||
|- |
|||
| Tigecycline |
|||
|76 |
|||
|≤0.03 to >0.5 |
|||
|0.12 |
|||
|0.25 |
|||
|ND |
|||
|- |
|||
| Rifampin |
|||
|76 |
|||
|≤0.5 to >4 |
|||
|≤0.5 |
|||
|≤0.5 |
|||
|97.4 |
|||
|- |
|||
| Quinupristin-dalfopristin |
|||
|76 |
|||
|≤0.5 to 4 |
|||
|≤0.5 |
|||
|2 |
|||
|89.5 |
|||
|- |
|||
| Linezolid |
|||
|76 |
|||
|≤1 |
|||
|≤1 |
|||
|≤1 |
|||
|100 |
|||
|- |
|||
| Gentamicin |
|||
|76 |
|||
|≤2 to >16 |
|||
|≤2 |
|||
|>16 |
|||
|81.6 |
|||
|- |
|||
| Daptomycin |
|||
|75 |
|||
|≤0.5 to >4 |
|||
|≤0.5 |
|||
|1 |
|||
|89.5 |
|||
|- |
|||
| Chloramphenicol |
|||
|75 |
|||
|≤2 to >16 |
|||
|4 |
|||
|16 |
|||
|ND |
|||
|- |
|||
| Nitrofurantoin |
|||
|76 |
|||
|≤32 to >64 |
|||
|>64 |
|||
|>64 |
|||
|ND |
|||
|} |
|||
{{DISPLAYTITLE:''Corynebacterium jeikeium''}} |
{{DISPLAYTITLE:''Corynebacterium jeikeium''}} |
||
[[Category:Gram-positive bacilli]] |
[[Category:Gram-positive bacilli]] |
Revision as of 14:37, 27 September 2023
- Species of Corynebacterium that causes opportunistic infections, most closely associated with hematologic stem cell transplant patients
- Clinical presentations include bacteremia, prosthetic valve endocarditis, meningitis, and peritonitis
- Essentially universally susceptible to vancomycin and linezolid
- High rates of resistance to beta lactams; may be fluoroquinolone or tetracycline susceptible[1]
Antibiotic | Isolates | % Susceptible |
---|---|---|
Penicillin | 76 | 0 |
Ampicillin | 76 | ND |
Oxacillin | 76 | ND |
Erythromycin | 76 | 11.8 |
Clindamycin | 76 | 2.6 |
Ciprofloxacin | 75 | 35.5 |
Levofloxacin | 75 | ND |
Moxifloxacin | 76 | 35.5 |
Tetracycline | 76 | 92.1 |
Vancomycin | 76 | 100 |
Trimethoprim-sulfamethoxazole | 76 | 18.4 |
Tigecycline | 76 | ND |
Rifampin | 76 | 97.4 |
Quinupristin-dalfopristin | 76 | 89.5 |
Linezolid | 76 | 100 |
Gentamicin | 76 | 81.6 |
Daptomycin | 75 | 89.5 |
Chloramphenicol | 75 | ND |
Nitrofurantoin | 76 | ND |
Penicillin | 76 | 0.5 to >8 | >8 | >8 | 0 |
Ampicillin | 76 | ≤0.12 to >8 | >8 | >8 | ND |
Oxacillin | 76 | 0.5 to >4 | >4 | >4 | ND |
Erythromycin | 76 | ≤0.25 to >4 | >4 | >4 | 11.8 |
Clindamycin | 76 | ≤0.5 to >2 | >2 | >2 | 2.6 |
Ciprofloxacin | 75 | ≤1 to >2 | >2 | >2 | 35.5 |
Levofloxacin | 75 | ≤0.25 to >4 | >4 | >4 | ND |
Moxifloxacinb | 76 | ≤0.25 to >4 | 4 | >4 | 35.5 |
Tetracycline | 76 | ≤2 to >16 | ≤2 | ≤2 | 92.1 |
Vancomycin | 76 | ≤0.25 to 2 | 0.50 | 1 | 100 |
Trimethoprim-sulfamethoxazole | 76 | ≤0.5 to >4 | >4 | >4 | 18.4 |
Tigecycline | 76 | ≤0.03 to >0.5 | 0.12 | 0.25 | ND |
Rifampin | 76 | ≤0.5 to >4 | ≤0.5 | ≤0.5 | 97.4 |
Quinupristin-dalfopristin | 76 | ≤0.5 to 4 | ≤0.5 | 2 | 89.5 |
Linezolid | 76 | ≤1 | ≤1 | ≤1 | 100 |
Gentamicin | 76 | ≤2 to >16 | ≤2 | >16 | 81.6 |
Daptomycin | 75 | ≤0.5 to >4 | ≤0.5 | 1 | 89.5 |
Chloramphenicol | 75 | ≤2 to >16 | 4 | 16 | ND |
Nitrofurantoin | 76 | ≤32 to >64 | >64 | >64 | ND |
- ↑ 1.0 1.1 Neemuchwala A, Soares D, Ravirajan V, Marchand-Austin A, Kus JV, Patel SN. In Vitro Antibiotic Susceptibility Pattern of Non-diphtheriae Corynebacterium Isolates in Ontario, Canada, from 2011 to 2016. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e01776-17. doi: 10.1128/AAC.01776-17. PMID: 29339389; PMCID: PMC5914010.